Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4354Neoplasms 3056Prostatic Neoplasms 1904Colorectal Neoplasms 1739Lung Neoplasms 1555Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Leukemia, Myeloid, Acute 952Multiple Myeloma 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 793Colonic Neoplasms 785Carcinoma, Hepatocellular 762Ovarian Neoplasms 757Melanoma 752Stomach Neoplasms 742Rectal Neoplasms 701Brain Neoplasms 696Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 607Lymphoma, Follicular 559Glioblastoma 541Recurrence 539Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × OTHER × Drug Resistant Epilepsy × Clear all
NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡